ストックスクリーナーアプリを入手
11.50
1.59%
0.18
アフターアワーズ：
11.62
0.12
+1.04%
前日終値:
$11.32
開ける：
$11.95
24時間の取引高:
1.11M
Relative Volume:
0.84
時価総額：
$537.08M
収益：
$20.72M
当期純損益:
$-100.84M
株価収益率:
-4.3233
EPS:
-2.66
ネットキャッシュフロー:
$-78.56M
1週間 パフォーマンス:
+1.41%
1か月 パフォーマンス:
+32.34%
6か月 パフォーマンス:
+241.25%
1年 パフォーマンス:
+43.57%
1日の値動き範囲:
$11.42
$12.00
1週間の範囲:
$10.87
$12.34
52週間の値動き範囲:
$2.235
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
名前
4 D Molecular Therapeutics Inc
セクター
電話
(510) 505-2680
住所
5858 HORTON STREET #455, EMERYVILLE
FDMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
11.50 | 528.67M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-13 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 開始されました | Morgan Stanley | Underweight |
| 2024-09-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 開始されました | Barclays | Overweight |
| 2024-02-07 | 再開されました | Goldman | Buy |
| 2023-10-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-18 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 開始されました | Chardan Capital Markets | Buy |
| 2023-01-30 | 開始されました | BMO Capital Markets | Outperform |
| 2022-11-18 | 開始されました | H.C. Wainwright | Buy |
| 2022-11-15 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-12 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 開始されました | Jefferies | Buy |
| 2022-01-04 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | BofA Securities | Buy |
| 2021-01-05 | 開始されました | Evercore ISI | Outperform |
| 2021-01-05 | 開始されました | Goldman | Neutral |
すべてを表示
4 D Molecular Therapeutics Inc (FDMT) 最新ニュース
4D Molecular Therapeutics (FDMT) Stock: Soars on $85M Otsuka Deal to Expand 4D-150 Across APAC - parameter.io
4D Molecular Shares Rise Premarket on Partnership With Otsuka - MarketScreener
4D Molecular Therapeutics Partners with Otsuka for APAC Market - TipRanks
4D Molecular (FDMT) Forms Key Partnership with Otsuka Pharmaceutical - GuruFocus
4D Molecular Therapeutics Announces Strategic Partnership with Otsuka Pharmaceutical Co. Ltd. to Develop and Commercialize 4D-150 for Treatment of Wet AMD and DME in APAC Region Including Japan - MarketScreener
4D Molecular Therapeutics Announces Strategic Partnership with Otsuka for Development of 4D-150 in Asia-Pacific Markets - Quiver Quantitative
4DMT (NASDAQ: FDMT) licenses 4D-150 to Otsuka in APAC; $85M upfront, $336M milestones - Stock Titan
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific - GlobeNewswire Inc.
How institutional ownership impacts 4D Molecular Therapeutics Inc. stockTreasury Yields & Daily Chart Pattern Signal Reports - newser.com
Backtesting results for 4D Molecular Therapeutics Inc. trading strategiesJuly 2025 PostEarnings & Community Trade Idea Sharing Platform - newser.com
Applying big data sentiment scoring on 4D Molecular Therapeutics Inc.2025 Dividend Review & Community Supported Trade Ideas - newser.com
4D Molecular Therapeutics Appoints New Financial Officer - MSN
Will 4D Molecular Therapeutics Inc. stock see insider buying2025 Stock Rankings & Proven Capital Preservation Methods - Fundação Cultural do Pará
What is the fair value of 4D Molecular Therapeutics Inc. stock now2025 Biggest Moves & AI Driven Stock Reports - newser.com
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update - TipRanks
4D Molecular Therapeutics Advances Gene Therapy for Wet AMD - TipRanks
4D Molecular Therapeutics Advances Gene Therapy Trial for Cystic Fibrosis - TipRanks
4D Molecular Therapeutics Advances Phase 3 Trial for Vision Loss Treatment - TipRanks
4D Molecular Therapeutics Advances Gene Therapy Trial for Fabry Disease - TipRanks
Published on: 2025-10-26 19:59:33 - newser.com
Why 4D Molecular Therapeutics Inc. stock remains on watchlists2025 Earnings Surprises & Stock Portfolio Risk Control - newser.com
4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development - Insider Monkey
4D Molecular Therapeutics’ (FDMT) “Outperform” Rating Reiterated at Royal Bank Of Canada - Defense World
Can 4D Molecular Therapeutics Inc. stock resist sector downturnsWeekly Profit Report & Free Real-Time Volume Trigger Notifications - newser.com
RBC Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT) - The Globe and Mail
RBC Capital Reiterates 4D Molecular Therapeutics (FDMT) Outperform Recommendation - Nasdaq
What recovery options are there for 4D Molecular Therapeutics Inc.Risk Management & Expert Approved Momentum Trade Ideas - newser.com
Bizily, 4D Molecular Therapeutics CLO, sells $16,627 in FDMT stock By Investing.com - Investing.com UK
How to build a dashboard for 4D Molecular Therapeutics Inc. stockOptions Play & Free Expert Verified Stock Movement Alerts - newser.com
Bizily, 4D Molecular Therapeutics CLO, sells $16,627 in FDMT stock - Investing.com India
4D Molecular Therapeutics Executive Sells Shares - TradingView
4D Molecular Therapeutics insider trade under 10b5-1 plan - Stock Titan
Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High? - MSN
Does 4D Molecular Therapeutics Inc. stock trade at a discount to peers2025 Pullback Review & Reliable Momentum Entry Alerts - nchmf.gov.vn
Will 4D Molecular Therapeutics Inc. stock benefit from AI adoption2025 Top Gainers & Real-Time Chart Pattern Alerts - nchmf.gov.vn
Leerink Partnrs Issues Optimistic Estimate for FDMT Earnings - Defense World
How 4D Molecular Therapeutics Inc. stock responds to policy changesTrade Volume Report & Free Growth Oriented Trading Recommendations - Trung tâm Dự báo KTTV quốc gia
4DMT Announces New Employment Inducement Grants - GlobeNewswire
Identifying reversal signals in 4D Molecular Therapeutics Inc.Portfolio Risk Summary & Safe Entry Trade Signal Reports - newser.com
4D Molecular Therapeutics Officer Sells Shares - TradingView
4D Molecular Therapeutics insider sale: 2,408 shares at $10 - Stock Titan
Will 4D Molecular Therapeutics Inc. outperform the marketMarket Performance Report & Verified Short-Term Trading Plans - newser.com
Retinitis Pigmentosa Market to Expand Significantly by 2034, States DelveInsight Report | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - The Globe and Mail
4D Molecular Therapeutics to Participate in Chardan’s 9th Annual Genetic Medicines Conference Panel Discussions - Quiver Quantitative
Can momentum traders help lift 4D Molecular Therapeutics Inc.Quarterly Investment Review & Daily Stock Trend Reports - newser.com
4D Molecular Therapeutics, Inc. announced that it expects to receive $11 million in funding from Cystic Fibrosis Foundation - MarketScreener
4 D Molecular Therapeutics Inc (FDMT) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):